- Home
- PRQR vs REFI Comparison
PRQR vs REFI Comparison
Compare PRQR & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | REFI |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 255.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRQR | REFI |
|---|---|---|
| Price | $2.17 | $13.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $8.14 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 634.1K | 119.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 15.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | $18,859,556.00 | ★ $54,287,847.00 |
| Revenue This Year | N/A | $13.78 |
| Revenue Next Year | $19.56 | $4.07 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $11.85 |
| 52 Week High | $3.10 | $16.29 |
Technical Indicators
Market Signals| Indicator | PRQR | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 55.08 |
| Support Level | $2.03 | $12.76 |
| Resistance Level | $2.25 | $13.25 |
| Average True Range (ATR) | 0.17 | 0.28 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 37.36 | 56.18 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.